Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D57NHD
|
|||
| Drug Name |
Zifibancimig
|
|||
| Synonyms |
RG6120
Click to Show/Hide
|
|||
| Indication | Neovascular age-related macular degeneration [ICD-11: 9B78.3Z; ICD-9: 362.5] | Phase 1 | [1] | |
| Company |
Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiopoietin-2 (ANGPT2) | Target Info | . | [2] |
| Vascular endothelial growth factor (VEGF) | Target Info | . | [2] | |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Angiogenesis | |||
| Pathway Interaction Database | Angiopoietin receptor Tie2-mediated signaling | |||
| Reactome | Tie2 Signaling | |||
| WikiPathways | Cell surface interactions at the vascular wall | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04567303) A Three-Part, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients With Neovascular Age-Related Macular Degeneration. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Roche | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.